Search

Your search keyword '"Hurteau, Jean A."' showing total 294 results
Start Over Author "Hurteau, Jean A."
294 results on '"Hurteau, Jean A."'

1. Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study.

Author

Chase, Dana, Shukla, Soham, Moore, Julia, Boyle, Tirza, Lim, Jonathan, Perhanidis, Jessica, Hurteau, Jean, and Schilder, Jeanne

Subjects
Electronic health records, First-line, Maintenance therapy, Niraparib, Ovarian cancer, Prognostic factors, Real-world, Time to next treatment
Abstract

INTRODUCTION: Niraparib first-line maintenance (1LM) therapy has demonstrated clinical benefit for patients with ovarian cancer (OC) in clinical trial and real-world settings, but data on factors associated with real-world patient outcomes remain limited. This analysis identified patient characteristics associated with time to next treatment (TTNT), a proxy for real-world progression-free survival, in patients with OC treated with 1LM niraparib monotherapy. METHODS: This retrospective observational study used a USA nationwide electronic health record-derived deidentified database and included adult patients diagnosed with OC who initiated 1LM niraparib monotherapy after first-line platinum-based chemotherapy. Patients were followed until the earliest occurrence of last clinical activity, death, or end of study period. TTNT was measured from 1LM niraparib initiation to the start of second-line treatment or death. Cox proportional hazards models assessed univariable and multivariable associations between baseline characteristics and TTNT. RESULTS: Of 7872 patients diagnosed with OC, 526 met the eligibility criteria and were included in this analysis. Median (IQR) duration of follow-up was 14.1 (7.4-23.6) months. In univariable analyses, age, BRCA/homologous recombination deficiency (HRD) status, socioeconomic status, stage at initial diagnosis, cytoreductive surgery type, and residual disease status were significantly associated with observed TTNT and were introduced into the multivariable model with other clinically relevant variables. In the multivariable analysis, BRCA/HRD status, cytoreductive surgery type, and residual disease status were significantly associated with observed TTNT after covariate adjustment. Conversely, age, Eastern Cooperative Oncology Group performance status, disease stage, niraparib starting dose status, and first-line bevacizumab use were not associated with observed TTNT. CONCLUSION: This real-world, retrospective, observational analysis offers valuable insights on prognostic factors associated with TTNT in patients with OC treated with 1LM niraparib monotherapy after first-line platinum-based chemotherapy. Future studies are needed to examine how additional patient characteristics associated with clinical outcomes may guide treatment decisions and improve outcomes.

Published
2024

3. Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting.

Author

Perhanidis, Jessica, Ghazarian, Armen, Du, Ella, Wang, Travis, Song, Jinlin, Golembesky, Amanda, Hurteau, Jean, Kalilani, Linda, Salani, Ritu, Monk, Bradley, Rimel, Bobbie, and Chase, Dana

Subjects
Advanced ovarian cancer, CYP450 inhibitor/inducer, Drug interactions, Poly(ADP ribose) polymerase inhibition
Abstract

Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi) are metabolized either via carboxylesterase (niraparib) or cytochrome P450 (CYP) enzymes (olaparib and rucaparib). Patients with advanced epithelial ovarian cancer (aOC) who receive concomitant medication metabolized by the CYP system may be at risk of drug-drug interactions impacting PARPi efficacy and tolerability. This study investigated CYP inhibitor/inducer treatment patterns in the first-line maintenance (1Lm) setting for patients with aOC. This retrospective cohort study used de-identified databases of US patients with aOC. Eligible patients were aged ≥18 years, diagnosed with aOC between January 2015-March 2021, and received CYP inhibitors/inducers during 1Lm PARPi initiation or the eligibility window (90 days before to 120 days after first-line platinum-based therapy ended [index]). Patients were either prescribed 1Lm PARPi monotherapy (PARPi cohort) or were not prescribed any 1Lm therapy within 120 days post-index (PARPi-eligible cohort). Strong/moderate CYP inhibitors/inducers were defined as area under the plasma concentration-time curve ratio (AUCR) ≥2 or clearance ratio (CL) ≤0.5 (inhibitors), and AUCR ≤0.5 or CL ratio ≥2 (inducers). Of 1411 patients (median age 63), 158 were prescribed PARPis and 1253 were PARPi-eligible. Among the PARPi cohort, 46.2%, 48.7%, and 5.1% were prescribed niraparib, olaparib, and rucaparib, respectively. For patients prescribed olaparib or rucaparib, 42.4% also received strong and/or moderate CYP inhibitors/inducers. This real-world study indicated a considerable proportion of patients received strong and/or moderate CYP inhibitors/inducers and were prescribed PARPis metabolized by the CYP system. Understanding potential impacts of concomitant CYP inhibitors/inducers on PARPi efficacy and safety is warranted.

Published
2024

4. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery

Author

Kim, Josephine S, Liang, Margaret I, Prendergast, Emily N, Alldredge, Jill, Datta, Avisek, Hurteau, Jean A, Kirschner, Carolyn V, Rodriguez, Gustavo, Vogel, Tilley J, Brooks, Rebecca A, Cass, Ilana, Cohen, Joshua G, Penner, Kristine R, Wang, Chi E, and Moore, Elena S Diaz

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Ovarian Cancer, Clinical Research, Rare Diseases, Cancer, Patient Safety, 6.4 Surgery, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Ovarian Epithelial, Chemotherapy, Adjuvant, Cohort Studies, Cytoreduction Surgical Procedures, Drug Administration Schedule, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Ovarian Neoplasms, Paclitaxel, Progression-Free Survival, Randomized Controlled Trials as Topic, Retrospective Studies, Time Factors, ovarian cancer, neoadjuvant chemotherapy, postoperative chemotherapy, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

ObjectivesTo compare clinical outcomes for stage IIIC and IV ovarian cancer patients receiving neoadjuvant chemotherapy and interval cytoreductive surgery followed by up to three versus more cycles of post-operative chemotherapy.MethodsWe conducted a multi-institution retrospective cohort study of patients treated from January 2005 to February 2016 with neoadjuvant platinum-based therapy followed by interval surgery and post-operative chemotherapy. The following were exclusion criteria: more than four cycles of neoadjuvant chemotherapy, bevacizumab with neoadjuvant chemotherapy, non-platinum therapy, prior chemotherapy, and elevated CA125 values after three post-operative chemotherapy cycles. Progression-free and overall survival and toxicity profiles were compared between groups receiving up to three cycles versus more that three cycles post-operatively.ResultsA total of 100 patients met inclusion criteria: 41 received up to three cycles and 59 received more than three cycles. The groups were similar in terms of age, body mass index, performance status, tumor histology, optimal cytoreduction rates, and median number of neoadjuvant chemotherapy cycles. Median progression-free survival was 14 vs 16.6 months in those receiving up to three cycles versus more than three cycles, respectively (HR 0.99, 95% CI 0.58 to 1.68, p=0.97). Similarly, median overall survival was not different at 47.1 vs 69.4 months, respectively (HR 1.96, 95% CI 0.87 to 4.42, p=0.10). There were no differences in grade 2 or higher chemotherapy-related toxicities.ConclusionsExtending post-operative chemotherapy beyond three cycles in patients receiving neoadjuvant chemotherapy and interval cytoreductive surgery with normalization of CA125 levels was not associated with improved survival or greater toxicity. Future study in a larger cohort is warranted to define optimal length of cytotoxic treatment.

Published
2019

6. The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

Author

Duska, Linda R., primary, Lim, Jonathan, additional, Boyle, Tirza Areli Calderón, additional, Guinter, Mark, additional, Halloran, Siobhan, additional, Hartman, John, additional, Schilder, Jeanne M., additional, Hurteau, Jean A., additional, and Golembesky, Amanda, additional

Published
2024
Full Text
View/download PDF

9. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Author

Vergote, Ignace, Scambia, Giovanni, Park, Sang Yoon, Song, Yong Sang, Makarova, Yulia, Trinidad, Joshua, Ngan, Hextan Yuen Sheung, Bamias, Aristotelis, Aravantinos, Gerasimos, Nam, Joo-Hyun, Gorbunova, Vera, Krikunova, Ludmila, Bae, Duk-Soo, Arija, Jose Angel Arranz, Mirza, Mansoor Raza, Zamagni, Claudio, Papandreou, Christos, Raspagliesi, Francesco, Lisyanskaya, Alla, Benzaquen, Ana Oaknin, Tognon, Germana, Ortega, Eugenia, Herraez, Antonio Casado, Buscema, Joseph, Green, Andrew, Burger, Robert, Sakaeva, Dina, Sanchez, Andres Redondo, Ghamande, Sharad, King, Laurel, Petru, Edgar, Peen, Ulla, Takeuchi, Satoshi, Ushijima, Kimio, Martin, Antonio Gonzalez, Kamelle, Scott, Carney, Michael, Marth, Christian, Forget, Frédéric, Bentley, James, Sehouli, Jalid, Colombo, Nicoletta, Zola, Paolo, Kato, Hidenori, Fadeeva, Natalya, Gotovkin, Evgeny, Vladimirov, Vladimir, Marin, Margarita Romeo, Alia, Eva Guerra, Shahin, Mark, Bhoola, Snehalkumar, Tewari, Krishnansu, Anderson, Daniel, Honhon, Brigitte, Pelgrims, Joseph (Gino), Oza, Amit, Jimenez, Jesus Garcia-Donas, Hansen, Vincent, O'Malley, David, Benjamin, Ivor, Renard, Vincent, Van den Bulck, Heidi, Meier, Werner, Haenle, Claudia, Koumakis, Georgios, Yokota, Harushige, Popov, Vadim, Bradley, William, Wenham, Robert, Reid, Robert, McNamara, Donna, Friedman, Richard, Barlin, Joyce, Spirtos, Nicola, Chapman, Julia, Sevelda, Paul, Huizing, Manon, Lamot, Caroline, Goffin, Frédéric, Hondt, Lionel D, Covens, Allan, Spadafora, Silvana, Rautenberg, Beate, Reimer, Toralf, Möbus, Volker, Hilpert, Felix, Gropp-Meier, Martina, Savarese, Antonella, Pignata, Sandro, Verderame, Francesco, Mizuno, Mika, Takano, Hirokuni, Ottevanger, Petronella, Velasco, Andres Poveda, Palacio-Vazquez, Isabel, Law, Amy, McIntyre, Kristi, Teneriello, Michael, Fields, Abbie, Lentz, Samuel, Street, Daron, Schwartz, Benjamin, Mannel, Robert, Lim, Peter, Pulaski, Heather, Janni, Wolfgang, Zorr, Andreas, Karck, Ulrich, Cheng, Ashley Chi Kin, Sorio, Roberto, Gridelli, Cesare, Aoki, Daisuke, Oishi, Tetsuro, Hirashima, Yasuyuki, Boere, Ingrid, Ferrer, Esther Falco, Braly, Patricia, Wilks, Sharon, Lee, Christine, Schilder, Jeanne, Veljovich, Dan, Secord, Angeles, Davis, Kevin, Rojas-Espaillat, Luis, Lele, Shashikant, DePasquale, Stephen, Squatrito, Robert, Schauer, Christian, Dirix, Luc, Vuylsteke, Peter, Joosens, Eric, Provencher, Diane, Lueck, Hans-Joachim, Hein, Alexander, Burges, Alexander, Canzler, Ulrich, Park-Simon, Tjoung-Won, Griesinger, Frank, Gadducci, Angiolo, Alabiso, Oscar, Okamoto, Aikou, Sawasaki, Takashi, Saito, Toshiaki, Ibañez, Ana Herrero, Calomeni, Coralia, Spillman, Monique, Choksi, Janak, Taylor, Nicholas, Muller, Carolyn, Moore, David, DiSilvestro, Paul, Cunningham, Mary, Rose, Peter, Oppelt, Peter, Verhoeven, Didier, Graas, Marie-Pascale, Ghatage, Prafull, Tonkin, Katia, Kurzeder, Christian, Schnappauf, Benjamin, Müller, Volkmar, Schmalzrie, Hannah, Kalofonos, Haralambos, Bruzzone, Milena, Kroep, Judith, Diaz, Cristina Caballero, Garcia, Jeronimo Martinez, Polo, Susana Hernando, Garrison, Mitchell, Rocconi, Rodney, Andrews, Stephen, Bristow, Robert, McHale, Michael, Basil, Jack, Houck III, William, Bell, Maria, Cosin, Jonathan, Modesitt, Susan, Kendrick, James, Wade III, James, Wong, Cheung, Evans, Anthony, Buekers, Thomas, Vanderkwaak, Timothy, Ferriss, James, Darus, Christopher, DAndre, Stacy, Higgins, Robert, Monk, Bradley, Bakkum-Gamez, Jamie, DeMars, Leslie, Van Le, Linda, Puls, Larry, Trehan, Shruti, LaPolla, James, Michelson, Elizabeth Dickson, Merchant, Joseph, Peterson, Christopher, Reid, Gary, Seago, Donald, Zweizig, Susan, Gajewski, Walter, Panwalkar, Amit, Leikermoser, Rudolf, Bogner, Gerhard, Debruyne, Philip, D'hondt, Randal, Berteloot, Patrick, Kerger, Joseph, Biagi, James, Castonguay, Vincent, Welch, Stephen, Muhic, Aida, Heubner, Martin, Grischke, Eva-Maria, Rack, Brigitte, Fleisch, Markus, Lordick, Florian, Pectasides, Dimitrios, Ho, Wing Ming, Selvaggi, Luigi, Vasquez, Flavia Morales, Villanueva, William Orlando Brito, Alavez, Alejandro Molina, Kessels, Lonneke, Bertran, Ana Santaballa, Fernandez, Cesar Mendiola, Fabregat, Miguel Beltran, Del Prete, Salvatore, Elkas, John, Cecchi, Gary, Kumar, Pallavi, Huh, Warner, Messing, Mark, Karimi, Misagh, Kelley, Ann, Edraki, Babak, Mutch, David, Leiserowitz, Gary, Anderson, Jeanne, Lentz, Scott, Chambers, Setsuko, Morris, Robert, Waggoner, Steven, Gordon, Alan, Method, Michael, Johnson, Peter, Lord, Raymond, Drake, Janet, Sivarajan, Kulumani, Midathada, Madhu, Rice, Kristen, Wadsworth, Troy, Pavelka, James, Edwards, Robert, Miller, David Scott, Ford, Patricia Locantore, Hurteau, Jean, Bender, David, Schimp, Veronica, Creasman, William, Lerner, Rachel, Chamberlain, Donald, Kueck, Angela, McDonald, John, Malad, Salman, Robinson-Bennett, Bernice, Davidson, Susan, Krivak, Thomas, Lestingi, Timothy, Arango, Hector, Berard, Paul, Finkelstein, Karen, Gaur, Rakesh, Krasner, Carolyn, Ueland, Frederick, Talmage, Lance, Yamada, Seiko, Sutton, Gregory, Potkul, Ronald, Prasad-Hayes, Monica, Osborne, Janet, Celano, Paul, Thigpen, James, Sharma, Sudarshan, Schilder, Russell, Tammela, Jonathan, Kemeny, Mary, Brown, Amy, Eisenhauer, Eric, Williams, James, Rowland, Kendrith, Nahum, Kenneth, Burke, James, Dar, Zahid, Fleming, Nicole, Gibb, Randall, Guirguis, Alfred, Herzog, Thomas, John, Veena, Kumar, Santhosh, Kamat, Aparna, Kassar, Mohamad, Leitao, Mario, Levine, Lyuba, Mendez, Luis, Patel, Dhimant, Berry, Emily, Warshal, David, Wolf, Judith, Zarwan, Corrine, Collins, Yvonne, Spitzer, Gary, Miller, Brigitte, Einstein, Mark, O'Malley, David M, Van Calster, Ben, Park, Sang-Yoon, del Campo, Josep M, Wenham, Robert M, Covens, Al, Raza Mirza, Mansoor, Kroep, Judith R, Ma, Haijun, Pickett, Cheryl A, and Monk, Bradley J

Published
2019
Full Text
View/download PDF

11. Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

Author

Herzog, Thomas J, primary, Wahab, Shaun A, additional, Mirza, Mansoor R, additional, Pothuri, Bhavana, additional, Vergote, Ignace, additional, Graybill, Whitney S, additional, Malinowska, Izabela A, additional, York, Whitney, additional, Hurteau, Jean A, additional, Gupta, Divya, additional, González-Martin, Antonio, additional, and Monk, Bradley J, additional

Published
2023
Full Text
View/download PDF

12. Real-world (RW) use of niraparib (Nir) monotherapy (mono) as first-line (1L) switch maintenance (1LSM) therapy following chemotherapy (CT) plus bevacizumab (bev) induction treatment in patients (pts) with epithelial ovarian cancer (EOC) in the SW1TCH study.

Author

Rimel, BJ, primary, Boyle, Tirza Areli Calderón, additional, Perhanidis, Jessica, additional, Burns, Sara, additional, Lim, Jonathan, additional, Hartman, John, additional, Kalilani, Linda, additional, Schilder, Jeanne M., additional, Hurteau, Jean A., additional, and Golembesky, Amanda, additional

Published
2023
Full Text
View/download PDF

15. Cancer of the Ovary, Uterus, and Cervix

Author

Brown, Jubilee, Hurteau, Jean, Reaman, Gregory H., Series editor, Smith, Franklin O., Series editor, Bleyer, Archie, editor, Barr, Ronald, editor, Ries, Lynn, editor, Whelan, Jeremy, editor, and Ferrari, Andrea, editor

Published
2017
Full Text
View/download PDF

16. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?

Author

Shah, Rachana, Xia, Caihong, Krailo, Mark, Amatruda, James F., Arul, Suren G., Billmire, Deborah F., Brady, William E., Covens, Allan, Gershenson, David M., Hale, Juliet P., Hurteau, Jean, Murray, Matthew J., Nicholson, James C., Olson, Thomas A., Pashankar, Farzana, Rodriguez-Galindo, Carlos, Shaikh, Furqan, Stark, Daniel, Frazier, A. Lindsay, and Stoneham, Sara

Published
2018
Full Text
View/download PDF

18. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.

Author

Hurteau, Jean A, Brady, Mark F, Darcy, Kathleen M, McGuire, William P, Edmonds, Pamela, Pearl, Michael L, Ivanov, Iouri, Tewari, Krishnansu S, Mannel, Robert S, Zanotti, Kristine, and Benbrook, Doris M

Subjects
Humans, Peritoneal Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasm Recurrence, Local, Thalidomide, Taxoids, Tamoxifen, Organoplatinum Compounds, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, CA-125 Antigen, Disease-Free Survival, Endpoint Determination, Administration, Oral, Aged, Aged, 80 and over, Middle Aged, Female, Bridged-Ring Compounds, Ovarian cancer, VEGF, CA-125, Recurrence, Neoplasm Recurrence, Local, Antineoplastic Agents, Hormonal, Administration, Oral, and over, Oncology & Carcinogenesis, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine
Abstract

PurposeTo compare progression-free survival (PFS), overall survival (OS) and toxicities of thalidomide versus tamoxifen and to evaluate serum vascular endothelial growth factor (VEGF) in biochemical-recurrent epithelial ovarian cancer, primary peritoneal cancer or fallopian tube carcinoma (EOC/PPC/FTC).MethodsBiochemical recurrence was defined as a rising CA-125 exceeding twice the upper limit of normal without evidence of disease as defined by RECIST 1.0 criteria. Women with FIGO stages III and IV, histologically confirmed EOC/PPC/FTC who were free of disease following first-line chemotherapy were randomized to oral thalidomide 200mg daily with escalation to a maximum of 400 mg or tamoxifen 20mg orally twice daily for up to 1 year, progression or adverse effect prohibited further treatment. VEGF was quantified by ELISA in pre and post-treatment serum.ResultsOf the 139 women randomized, 138 were eligible. Interim analysis showed that thalidomide did not reduce the recurrence rate relative to tamoxifen, and the trial was closed. Thalidomide versus tamoxifen was associated with a similar risk of progression (HR = 1.31, 95% confidence interval [CI] = 0.93-1.85), an increased risk of death (HR = 1.76, 95% CI = 1.16-2.68) and more grades 3 and 4 toxicities (55% versus 3%). The most common grades 3 and 4 toxicities were constitutional (12%), somnolence (12%), pulmonary (9%), venous thromboembolism (VTE) (6%) and peripheral neurologic (6%) for thalidomide, with VTE (1.4%) and gastrointestinal (1.4%) for tamoxifen. Serum VEGF was not associated with clinical characteristics, treatment, PFS or OS.ConclusionThalidomide was not more effective than tamoxifen in delaying recurrence or death but was more toxic. VEGF was not prognostic in this cohort.

Published
2010

19. Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting

Author

Rimel, Bobbie J., Chase, Dana M., Perhanidis, Jessica, Ghazarian, Armen A., Du, Ella Xiaoyan, Wang, Travis, Song, Jinlin, Golembesky, Amanda K., Hurteau, Jean A., Kalilani, Linda, Salani, Ritu, and Monk, Bradley J.

Published
2024
Full Text
View/download PDF

23. EP224/#531 Optimization of assessment of disease progression between blinded central independent review and investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial

Author

Herzog, Thomas, primary, Wahab, Shaun A, additional, Mirza, Mansoor, additional, Pothuri, Bhavana, additional, Vergote, Ignace, additional, Graybill, Whitney S, additional, Malinowska, Izabela A, additional, York, Whitney, additional, Hurteau, Jean A, additional, Gupta, Divya, additional, Gonzalez-Martin, Antonio, additional, and Monk, Bradley, additional

Published
2022
Full Text
View/download PDF

24. 2022-RA-708-ESGO Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?

Author

Backes, Floor, primary, Calderón Boyle, Tirza Areli, additional, Perhanidis, Jessica, additional, Lim, Jonathan, additional, Kalilani, Linda, additional, Hurteau, Jean A, additional, Golembesky, Amanda, additional, and Salani, Ritu, additional

Published
2022
Full Text
View/download PDF

25. 2022-RA-618-ESGO Who receives maintenance therapy after first-line chemotherapy? a real-world assessment of patients with ovarian cancer who received niraparib first-line maintenance therapy in the United States

Author

Salani, Ritu, primary, Calderón Boyle, Tirza Areli, additional, Perhanidis, Jessica, additional, Lim, Jonathan, additional, Kalilani, Linda, additional, Hurteau, Jean A, additional, Golembesky, Amanda, additional, and Backes, Floor, additional

Published
2022
Full Text
View/download PDF

26. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Author

Liu, Joyce F, Barry, William T, Birrer, Michael, Lee, Jung-Min, Buckanovich, Ronald J, Fleming, Gini F, Rimel, BJ, Buss, Mary K, Nattam, Sreenivasa, Hurteau, Jean, Luo, Weixiu, Quy, Philippa, Whalen, Christin, Obermayer, Lisa, Lee, Hang, Winer, Eric P, Kohn, Elise C, Ivy, S Percy, and Matulonis, Ursula A

Published
2014
Full Text
View/download PDF

27. Ovarian Yolk Sac Tumors; Does Age Matter?

Author

Faure Conter, Cecile, Xia, Caihong, Gershenson, David, Hurteau, Jean, Covens, Al, Pashankar, Farzana, Krailo, Mark, Billmire, Deborah, Patte, Catherine, Fresneau, Brice, Shaikh, Furqan, Stoneham, Sara, Nicholson, James, Murray, Matthew, and Frazier, Anne Lindsay

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results